Receptos Announces Positive Results for Ulcerative Colitis Therapy in Maintenance Period of Phase 2 Trial

Receptos Announces Positive Results for Ulcerative Colitis Therapy in Maintenance Period of Phase 2 Trial
Receptos, Inc. a biopharmaceutical company that develops drug candidates for the treatment of immune and metabolic diseases, recently announced positive results for the maintenance period of TOUCHSTONE, a Phase 2 clinical study examining the efficacy of ozanimod (previously known as RPC1063) for the treatment of ulcerative colitis (UC). According to a recent news release, after 32 weeks of treatment, the study met all the established efficacy endpoints with statistical significance for those patients under a dosing of 1 mg. The tolerability and overall safety profile of ozanimod in this Phase 2 trial was in line with the results observed with the study induction period and also with those seen in another Phase 2 trial called RADIANCE that tested the drug candidate in patients with relapsing multiple sclerosis (RMS). These results support the efficacy of ozanimod (orally administrated) to improve the treatment of patients with UC. TOUCHSTONE is a double-blind, randomized, placebo-controlled trial that evaluated the safety, tolerability and efficacy in 199 patients with moderate to severe UC that received one of two doses of ozanimod (0.5 mg and 1 mg) or a placebo. The trial was conducted in 13 countries across 57 research sites. Results from the induction period revealed that the study met all its primary efficacy and all secondary endpoints after
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *